Global Migraine Market Report: 2016 Edition
Migraine is a common neurovascular disorder that is characterized by throbbing headaches and is commonly associated with other neurological symptoms, such as nausea, vomiting, and painful sensitivity to lights and sounds. Migraines are thought to result from the activation and sensitization of sensory neurons that have nerve endings in meningeal blood vessels. Migraines can be episodic or chronic. Chronic Migraine (CM) and Episodic Migraine (EM) are both part of the spectrum of migraine disorders, but are distinct clinical entities. The onset of migraine is preceded by certain triggers, which can be unique for each migraine sufferer.
Triptans and Ergots are among the most common drug options existing in the treatment market for migraine. The global migraine treatment market currently faces several unmet needs and is saturated with the availability of generic drugs. Several branded drugs are under development with safer and more effective profiles, given the vast opportunities existing in the market. The focus of upcoming drugs is to either cure migraine or to reduce the frequency to a level where patients can find tolerable relief.
The migraine market is expected to acquire modest growth driven by launch of new therapies and increasing rate of drug treatment due to increasing female population and rising awareness among physicians and patients. The major growth drivers of the migraine market includes rising spending on medicines, growing female population, increasing cigarette consumption and healthcare expenditure. However, the growth of the market will also remain challenged by complications associated with Triptans, treatment limitations for patients with CV (Cardio Vascular) risk and increased preference for OTC (Over the Counter) medications.
The report, “Global Migraine Market” analyzes the currently prevailing condition of the market along with its future scope of development. The specific market of the U.S. is being discussed in the report. The major trends, growth drivers as well as issues being faced by the industry are being presented in this report. The major players in the industry are being profiled, along with their key financials and strategies for growth.
Triptans and Ergots are among the most common drug options existing in the treatment market for migraine. The global migraine treatment market currently faces several unmet needs and is saturated with the availability of generic drugs. Several branded drugs are under development with safer and more effective profiles, given the vast opportunities existing in the market. The focus of upcoming drugs is to either cure migraine or to reduce the frequency to a level where patients can find tolerable relief.
The migraine market is expected to acquire modest growth driven by launch of new therapies and increasing rate of drug treatment due to increasing female population and rising awareness among physicians and patients. The major growth drivers of the migraine market includes rising spending on medicines, growing female population, increasing cigarette consumption and healthcare expenditure. However, the growth of the market will also remain challenged by complications associated with Triptans, treatment limitations for patients with CV (Cardio Vascular) risk and increased preference for OTC (Over the Counter) medications.
The report, “Global Migraine Market” analyzes the currently prevailing condition of the market along with its future scope of development. The specific market of the U.S. is being discussed in the report. The major trends, growth drivers as well as issues being faced by the industry are being presented in this report. The major players in the industry are being profiled, along with their key financials and strategies for growth.
1. MARKET OVERVIEW
1.1 Introduction
1.2 Types
1.3 Causes and Pathogenesis
1.4 Symptoms and Diagnosis
1.5 Treatment Options
2. GLOBAL MIGRAINE MARKET
2.1 Global Migraine Drug Market by Value
2.2 Global Migraine Drug Market by Category
2.3 Global Therapeutic Botulinum Toxin Market by Value
2.4 Global Therapeutic Botulinum Toxin Market by Indication
3. THE U.S. MIGRAINE MARKET
3.1 The U.S. Total Migraine Population
3.2 The U.S. Migraine Population by Diagnosis
3.3 The U.S. Migraine Population with CV Risk Factors
3.4 The U.S Preventive Migraine Treatment by Specialty
3.5 The U.S. Acute Migraine Treated Population by Drug Type
3.6 The U.S. Acute Migraine Prescription Volume
3.7 The U.S. Migraine Drugs Revenue
3.7.1 Cambia
3.7.2 Lasmiditan
4. MARKET DYNAMICS
4.1 Growth Drivers
4.1.1 Rising Spending on Medicines
4.1.2 Growing Female Population
4.1.3 Increasing Cigarette Consumption
4.1.4 Rising Healthcare Expenditure
4.2 Trends
4.2.1 Emergence of Peripheral Nerve Stimulators
4.2.2 Increased Preference for Non Pharmacological Treatment
4.2.3 Higher Prevalence of Migraine than Other Chronic Diseases
4.2.4 Recurrent Symptoms in Migraine Patients
4.2.5 Drugs under Development for Migraine
4.3 Challenges
4.3.1 Complications associated with Triptans
4.3.2 Treatment Limitations for Patients with Cardiovascular Disease
4.3.3 Rise in Prescription Drugs to OTC Switch
5. COMPETITIVE LANDSCAPE
6. COMPANY PROFILES
6.1 Amgen Inc.
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Teva Pharmaceuticals
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Eli Lilly and Company
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 AstraZeneca
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
1.1 Introduction
1.2 Types
1.3 Causes and Pathogenesis
1.4 Symptoms and Diagnosis
1.5 Treatment Options
2. GLOBAL MIGRAINE MARKET
2.1 Global Migraine Drug Market by Value
2.2 Global Migraine Drug Market by Category
2.3 Global Therapeutic Botulinum Toxin Market by Value
2.4 Global Therapeutic Botulinum Toxin Market by Indication
3. THE U.S. MIGRAINE MARKET
3.1 The U.S. Total Migraine Population
3.2 The U.S. Migraine Population by Diagnosis
3.3 The U.S. Migraine Population with CV Risk Factors
3.4 The U.S Preventive Migraine Treatment by Specialty
3.5 The U.S. Acute Migraine Treated Population by Drug Type
3.6 The U.S. Acute Migraine Prescription Volume
3.7 The U.S. Migraine Drugs Revenue
3.7.1 Cambia
3.7.2 Lasmiditan
4. MARKET DYNAMICS
4.1 Growth Drivers
4.1.1 Rising Spending on Medicines
4.1.2 Growing Female Population
4.1.3 Increasing Cigarette Consumption
4.1.4 Rising Healthcare Expenditure
4.2 Trends
4.2.1 Emergence of Peripheral Nerve Stimulators
4.2.2 Increased Preference for Non Pharmacological Treatment
4.2.3 Higher Prevalence of Migraine than Other Chronic Diseases
4.2.4 Recurrent Symptoms in Migraine Patients
4.2.5 Drugs under Development for Migraine
4.3 Challenges
4.3.1 Complications associated with Triptans
4.3.2 Treatment Limitations for Patients with Cardiovascular Disease
4.3.3 Rise in Prescription Drugs to OTC Switch
5. COMPETITIVE LANDSCAPE
6. COMPANY PROFILES
6.1 Amgen Inc.
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Teva Pharmaceuticals
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Eli Lilly and Company
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 AstraZeneca
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
LIST OF CHARTS
Global Migraine Drug Market by Value (2013-2020E)
Global Migraine Drug Market by Category (2015E)
Global Therapeutic Botulinum Toxin Market (2013-2020E)
Global Therapeutic Botulinum Toxin Market by Indication (2015)
The U.S. Total Migraine Population (2015-2022E)
The U.S. Migraine Population by Diagnosis (2015E)
The U.S. Migraine Population with CV Risk Factors (2015-2022E)
The U.S. Preventive Migraine Treatment by Specialty (2015)
The U.S. Acute Migraine Treated Population by Drug Type (2014)
The U.S. Acute Migraine Prescription Volume (2015-2025E)
The U.S. Cambia Drug Revenue (2015-2022E)
The U.S. Lasmiditan Drug Revenue & Treated Patient (2015-2022E)
Global Spending on Medicines (2010-2020E)
Pharmaceutical Spending Per Capita by Country (2015)
Global Female Population (2010-2015)
Global Cigarette Consumption (1910-2014)
Global Healthcare Expenditure (2010-2015E)
Global FDA Neuromodulator Trials by Category (2014)
Reasons for Initiation of VNS Therapy among Patients (2015)
Reasons for Continuation of VNS Therapy among Patients (2015)
Percentage of People Affected in the U.S. (2014)
Common Symptoms in Migraine Patients (2015)
Global Over the Counter (OTC) Drug Market (2010-2014)
Amgen Inc. Revenue Share by Geography (2015)
Amgen Inc. Revenue and Net Income (2011-2015)
Amgen Inc. Research and Development Expenditure (2011-2015)
Teva Pharmaceuticals Product Sales by Segment (2015)
Teva Pharmaceuticals Revenue and Net Income (2011-2015)
Teva Pharmaceuticals Research & Development Expenditure (2011-2015)
Eli Lilly Revenue by Segments (2015)
Revenue and Net Income of Eli Lilly and Company (2011-2015)
Research and Development Expenditure of Eli Lilly (2011-2015)
AstraZeneca Revenue by Therapeutic Segment (2015)
AstraZeneca Revenue by Regions (2015)
AstraZeneca Revenue and Net profit (2010-2015)
Global Migraine Drug Market by Value (2013-2020E)
Global Migraine Drug Market by Category (2015E)
Global Therapeutic Botulinum Toxin Market (2013-2020E)
Global Therapeutic Botulinum Toxin Market by Indication (2015)
The U.S. Total Migraine Population (2015-2022E)
The U.S. Migraine Population by Diagnosis (2015E)
The U.S. Migraine Population with CV Risk Factors (2015-2022E)
The U.S. Preventive Migraine Treatment by Specialty (2015)
The U.S. Acute Migraine Treated Population by Drug Type (2014)
The U.S. Acute Migraine Prescription Volume (2015-2025E)
The U.S. Cambia Drug Revenue (2015-2022E)
The U.S. Lasmiditan Drug Revenue & Treated Patient (2015-2022E)
Global Spending on Medicines (2010-2020E)
Pharmaceutical Spending Per Capita by Country (2015)
Global Female Population (2010-2015)
Global Cigarette Consumption (1910-2014)
Global Healthcare Expenditure (2010-2015E)
Global FDA Neuromodulator Trials by Category (2014)
Reasons for Initiation of VNS Therapy among Patients (2015)
Reasons for Continuation of VNS Therapy among Patients (2015)
Percentage of People Affected in the U.S. (2014)
Common Symptoms in Migraine Patients (2015)
Global Over the Counter (OTC) Drug Market (2010-2014)
Amgen Inc. Revenue Share by Geography (2015)
Amgen Inc. Revenue and Net Income (2011-2015)
Amgen Inc. Research and Development Expenditure (2011-2015)
Teva Pharmaceuticals Product Sales by Segment (2015)
Teva Pharmaceuticals Revenue and Net Income (2011-2015)
Teva Pharmaceuticals Research & Development Expenditure (2011-2015)
Eli Lilly Revenue by Segments (2015)
Revenue and Net Income of Eli Lilly and Company (2011-2015)
Research and Development Expenditure of Eli Lilly (2011-2015)
AstraZeneca Revenue by Therapeutic Segment (2015)
AstraZeneca Revenue by Regions (2015)
AstraZeneca Revenue and Net profit (2010-2015)
LIST OF TABLES
Common Migraine Triggers
Current Treatment Options for Moderate to Severe Episodic Migraine
Non-Triptans Migraine Drugs under Development
Global Migraine Competitors Comparison (2015)
Product and Other Acquisitions of Eli Lilly
Common Migraine Triggers
Current Treatment Options for Moderate to Severe Episodic Migraine
Non-Triptans Migraine Drugs under Development
Global Migraine Competitors Comparison (2015)
Product and Other Acquisitions of Eli Lilly
